Hexahydrocurcumin suppresses hepatocellular carcinoma by regulating TRIM23/MBNL1 pathway.

ABSTRACT: Hepatocellular carcinoma (HCC) ranks among the most prevalent malignant tumors worldwide, characterized by high mortality rates. TRIM23, an E3 ubiquitin ligase, represents a potential molecular target for anticancer drug development. Additionally, Hexahydrocurcumin (HHC) exhibits notable anticancer activity as a natural product. Here, we aimed to investigate HHC's anti-tumor role in HCC. Molecular docking assays and Cellular thermal shift assays were employed to predict HHC's potential targeting of TRIM23. Immunofluorescence and western blot analyses were conducted to assess HHC's inhibition of TRIM23 expression. Wound-healing, clone formation, and transwell assays were used to evaluate its anti-tumor efficacy. Quantitative proteome analysis and co-immunoprecipitation (Co-IP) were employed

SUBMITTER: Wang M 

PROVIDER: S-EPMC12218974 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature